Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
1 other identifier
observational
90
1 country
1
Brief Summary
Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease, and proteinuria isn't determent factor for the end stage renal disease in diabetics. Apelin is adipokine and have a beneficial role in early prediction of diabetic nephropathy. Few studies were done about apelin in diabetes. Purpose of the study: to investigate the association between the apelinergic system and diabetic nephropathy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 29, 2020
CompletedFirst Submitted
Initial submission to the registry
May 5, 2020
CompletedFirst Posted
Study publicly available on registry
May 8, 2020
CompletedMay 11, 2020
May 1, 2020
4 months
May 5, 2020
May 7, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
prediction of diabetic nephropathy
the use of plasma apelin level as a predictor for development of diabetic nephropathy
12 weeks
Study Arms (3)
I
30 patients with type 2 DM with nephropathy
II
30 type 2 DM without nephropathy
III
30 non DM as control group
Interventions
Eligibility Criteria
90 patients aged 20 to 65 years, 30 healthy subjects as a control group and 60 patients with type 2 DM .Patients were collected from the endocrinology 84 outpatient clinic, Kasr El Ainy, Cairo university
You may qualify if:
- type 2 diabetes patients of both sexes ,20-60 years of age
You may not qualify if:
- Patients with nephropathy due to other causes than diabetes, hepatic, intrinsic renal or coronary artery disease, patients with diabetic neuropathy and retinopathy and hypertensive patient on angiotensin receptor blockers (ARBS) or angiotensin converting enzyme inhibitors (ACEI)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Cairo university hospitals
Cairo, Manial, 12511, Egypt
Related Publications (1)
1. American Diabetes Association (ADA) .2012. Diagnosis of diabetes mellitus.2012 .Diabetes 291 Care;35. suppl S64- S71. doi: 10.2337/dc12-s064 . 292 2. Bonnet F and Cooper ME. 2000. Potential influence of lipids in diabetic nephropathy:insights 293 from experimental data and clinical studies. Diabetes Metab.;26:254-64. 294 3. Chan YH. 2003: Biostatistics102: Quantitative Data - Parametric & Non-parametric Tests. 295 Singapore Med J.;44(8): 391-396. 296 4. Chan YH. 2003: Biostatistics 104: Correlational Analysis. Singapore Med J.;44(12) : 614- 297 619.
BACKGROUND
Biospecimen
serum Apelin
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 12 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of internal medicine
Study Record Dates
First Submitted
May 5, 2020
First Posted
May 8, 2020
Study Start
November 30, 2019
Primary Completion
March 20, 2020
Study Completion
March 29, 2020
Last Updated
May 11, 2020
Record last verified: 2020-05
Data Sharing
- IPD Sharing
- Will not share
no sharing